Strictly private and confidential Digital Health Transformation An

  • Slides: 21
Download presentation
Strictly private and confidential Digital Health Transformation An AI and Big Data Platform for

Strictly private and confidential Digital Health Transformation An AI and Big Data Platform for Effective Cures June-2018

Disclaimer • This document (the “Document”) is being provided by Parnassus Medical Systems. •

Disclaimer • This document (the “Document”) is being provided by Parnassus Medical Systems. • This Document is confidential and should not be distributed or disclosed to any third party without the prior written consent of Parnassus Medical System. • This Document has been prepared on the basis of publicly available information. • This Document does not constitute an audit or a due diligence review and should not be construed as such. No representation or warranty, express or implied, is or will be made and no responsibility or liability is or will be accepted by Parnassus Medical Systems as to or in relation to the accuracy or completeness of the information forming the basis of this Document, or for any errors, inaccuracies or omissions.

We Spent A LOT in Healthcare US Healthcare spending is 18. 3% of GDP

We Spent A LOT in Healthcare US Healthcare spending is 18. 3% of GDP and ~$3. 5 trillions in 2017. The highest in all countries. Privileged Information of PMS

But. . . Privileged Information of PMS

But. . . Privileged Information of PMS

Even Worse … Privileged Information of PMS

Even Worse … Privileged Information of PMS

Solutions: Intelligent Digital Health Services Quality Outcomes Population Health Safety/ REMS Education Coordinated Care

Solutions: Intelligent Digital Health Services Quality Outcomes Population Health Safety/ REMS Education Coordinated Care Clinical trials Community Outreach Research Artificial Intelligence (AI) and Analytics Layer Best-of-breed solution & total cost of ownership Enterprise Integrative Data Layer at Health Systems

Current Product Pipeline 1. AI App in Breast Cancer Risk Assessment (BRISK) [Current Focus]

Current Product Pipeline 1. AI App in Breast Cancer Risk Assessment (BRISK) [Current Focus] 1. Methodist Hospital Cancer Health App (MOCHA) for Transition/Coordination Care of Cancer Survivors and Patients 1. AI App in Predicting Patient Fall with Harm 1. AI App in Predicting Patient Risk of Readmissions (Re-Admit) * All these apps are developed in Dr. Stephen Wong’s Lab at Houston Methodist and have been clinically tested and validated at Houston Methodist Hospital. Privileged Information of PMS

Breast Cancer Risk Assessment - Pain Point • In the US, ~1. 7 million

Breast Cancer Risk Assessment - Pain Point • In the US, ~1. 7 million new cancer cases are identified annually. Breast and lung cancers account for ~27% of all the new cases. o Breast: 232, 670 o Lung: 224, 210 • To date, imaging modalities (mammography, CT, PET, etc. ) have been the primary method used for assessing risks of breast and lung cancers. • However, a number of studies have shown these technologies to have relative high false positive rates. Privileged Information of PMS

Solution: AI Provides Precise Breast Cancer Risk Scores • Address overdiagnosis and overbiopsy issues

Solution: AI Provides Precise Breast Cancer Risk Scores • Address overdiagnosis and overbiopsy issues in breast cancer • Provide more precise risk assessment • A patient-physician engagement tool Mammography Ultrasound Unstructured Clinical Reports Image Processing Image Features Natural Language Processing Clinical Information (NLP) Signatures Biopsy Score Risk Assessment Autoencoder-Deep Learning Model Privileged Information of PMS Imagomics Knowledge Database Patel TJ, et. al, Cancer 2017 Jan 1; 123(1): 114 -121.

Breast Cancer Risk Assessment - Market • Breast Cancer: o American Cancer Society recommends

Breast Cancer Risk Assessment - Market • Breast Cancer: o American Cancer Society recommends annual/bi-annual mammograms women over 44 years old, resulting in ~23 million mammograms per year. o False positive rate from mammogram is estimated to be 7%~10%[1]. § False positive rate of ductal carcinoma in situ (DCIS) is estimated to be 86%[2] o Some researchers have estimated false positive mammograms are costing approximately $4 billion per year [3]. 1. 2. 3. https: //www. cancer. gov/types/breast/hp/breast-screening-pdq https: //www. medscape. com/viewarticle/842820 https: //www. healthaffairs. org/doi/full/10. 1377/hlthaff. 2014. 1087 Privileged Information of PMS

Market: Cost Reduction (US alone) • Breast Cancer: Simply reducing false positive rate from

Market: Cost Reduction (US alone) • Breast Cancer: Simply reducing false positive rate from 7% to 4% can save ~ $600 M annually Estimated Cost Reduction Diagnostic Imaging = $133 Other Imaging = $54 Biopsy = $101 Prophylatic Mastectomy = $15 DCIS = $292 Privileged Information of PMS

Primary Customers – Equipment Vendors q The AI predictive system can be licensed to

Primary Customers – Equipment Vendors q The AI predictive system can be licensed to equipment manufacturers. q An imaging system with an ability to learn from prior images can significantly reduce false positive rate; thus, mitigating the high false positive concern and imaging frequency. q The enhanced imaging system can assist diagnosing physician(s) to make more informed treatment decisions. q The enhanced imaging system can reduce the number of undue patient anxieties resulting from false positive results. Privileged Information of PMS

Secondary Customers – Payors (Insurance Firms) q The algorithm can be licensed to health

Secondary Customers – Payors (Insurance Firms) q The algorithm can be licensed to health insurance companies. q Insurance companies can benefit significantly from checking against overclaims of false positive findings. q As a part of utilization management (prior authorization) for diagnostic and biopsy, insurance companies can require providers to submit imaging data and corresponding medical records. Privileged Information of PMS

Competition + +

Competition + +

Press and Award Artificial Intelligence Is Helping Doctors Find Breast Cancer Risk 30 Times

Press and Award Artificial Intelligence Is Helping Doctors Find Breast Cancer Risk 30 Times Faster Aug 29, 2016 Silicon Valley Innovation And Entrepreneurship Forum (SVIEF) 2 nd Prize Oct 1, 2016 Privileged Information of PMS

Press and Award AI, Deep Learning and Body Sensor Networks for Healthcare Transformation Mar

Press and Award AI, Deep Learning and Body Sensor Networks for Healthcare Transformation Mar 6 th , 2018 Privileged Information of PMS

Product Development Plan 1) Concept Study (Close to completed) o Investigating applications of AI

Product Development Plan 1) Concept Study (Close to completed) o Investigating applications of AI algorithms and risk modeling for breast cancer cases, expected preliminary results in 3 months. o Our goal is to increase specificity to 97. 4%, i. e. , 50% reduction in false positive rate. 2) Feasibility Study Once the feasibility study goal is achieved a broader study (double blinded, multiple cancer center) will be required. 3) Approval FDA approval for medical device may be required. 4) Next Product in the Pipeline: Incidental Lung Cancer Risk Assessment. Privileged Information of PMS

Alliance Technology Licenser and Clinical Partner Houston Methodist Hospital is the flagship hospital of

Alliance Technology Licenser and Clinical Partner Houston Methodist Hospital is the flagship hospital of Houston Methodist. The hospital has consistently ranked as "One of America's Best Hospitals" according to U. S. News and World Report. The hospital has earned worldwide recognition in multiple specialties including cardiovascular surgery, cancer, epilepsy treatment and organ transplantation. Privileged Information of PMS Commercial Partner Health 2047 is a Silicon Valley innovation enterprise, developing and commercializing healthcare solutions. Working together with the American Medical Association (AMA), Health 2047 is creating an ecosystem of best-in-class partners who work together to tackle our largest healthcare challenges.

Investment Highlights We are looking for 18 months financing of $1 -2 M to

Investment Highlights We are looking for 18 months financing of $1 -2 M to 1) complete the prototype and 2) increase specificity to 97. 4%, i. e. , 50% reduction in false positive rate. Pre-Money $7 M $ 0. 7 M 1) Feasibility Study $ 1 -2 M Angel Fund Series Pre-A Round 2) Approval FDA approval for medical device may be required. (Current) Series A Round ($8 -10 M, Projected) Privileged Information of PMS

Founding Team § Chief Research Information Officer and Chair of Systems Medicine at Houston

Founding Team § Chief Research Information Officer and Chair of Systems Medicine at Houston Methodist. John Dunn Presidential Distinguished Chair Professor at Cornell University; former Professor at Harvard and UCSF. § Directed HCNR Center for Bioinformatics at Harvard Medical School; the Functional and Molecular Imaging Center at Brigham and Women’s hospital; enterprise image management system implementation at UCSF. Stephen TC Wong § Ph. D, PE 30 years of experiences in technical and executive roles in major technology-driven companies including HP, AT&T Microelectronics & Bell Labs, Philips Healthcare, and Charles Schwab, where he developed and produced an electronic trading platform. § Former Founding Director at Biomanufacturing Research Institute and Technology Enterprise Institute at North Carolina Central University (NCCU), Durham, North Carolina. § 30 years of experience in drug discovery research of neurodegeneration and cancer by working in major pharmaceutical and small biotechnology companies, including Pfizer, Eli Lilly, and Perkin Elmer. § Led the formation of formal biotech degree programs at NCCU of 50 faculty. § Senior Operations Manager at Houston Methodist. § Former Regional Manager with Gen. Script Corp (HKG: 1548) that developed the first CART therapy accepted for review by the CFDA. He was in charge of business development, marketing channels, and new product launch. Li-An Yeh, Ph. D (CEO) § 10 years of expertise in business development, technology valuation, marketing and sales Tian Ding, Ph. D, MBA management, financial modeling and budgeting.

Advisory Board Jenny Chang, MD Kenneth Kiosk, MD Professor & Chair, Houston Methodist Hospital

Advisory Board Jenny Chang, MD Kenneth Kiosk, MD Professor & Chair, Houston Methodist Hospital Professor, UC Santa Barbara Mark Zhang, MS CTO & SVP, IGG. COM Privileged Information of PMS Norbert Perrimon, Ph. D Stephen Wong, Ph. D, PE Professor & HHMI, Harvard University Professor & Chair, Houston Methodist Hospital